ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amicus buys gene therapy firm Celenex

by Lisa M. Jarvis
September 21, 2018 | APPEARED IN VOLUME 96, ISSUE 38

 

Rare disease-focused Amicus Therapeutics is shelling out $100 million up front, and up to $350 million more in milestones, for the privately held gene therapy developer Celenex. The acquisition gives Amicus the rights to 10 gene therapy programs that were originally developed at the Center for Gene Therapy at Nationwide Children’s Hospital and Ohio State University. The three most advanced gene therapies each address a subtype of a rare, deadly, inherited nervous system disorder called Batten disease. The deal marks Amicus’s entry into gene therapy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment